Adcock Ingram gets profit bump as drug demand begins normalising
SA’s cold and flu season was largely absent in 2020, but the company says improved demand and innovative marketing helped it in 2021
23 February 2022 - 08:32
UPDATED 23 February 2022 - 14:20
Adcock Ingram, which counts Panado painkillers and the cold and flu product Corenza C among its brands, says an improvement in demand for over-the-counter (OTC) products and innovative marketing helped it grow trading profit by a quarter in its half year to end-December.
New products, such as additional Panado variants, helped boost Adcock’s consumer business to well above pre-pandemic levels, CEO Andy Hall told Business Day, with the group pleased by improved margins and about R200m in revenue from products that weren’t in the market a year ago...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.